Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSisram Med
Stock Code01696
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是全球領先的能量源醫療美容器械供應商,具有自主設計、研發及生產能力,通常採用自有創新及專利技術。開發及生產用於無創及微創醫療美容治療的醫療美容器械,包括脫毛、嫩膚、靚膚、血管治療及色素性病變治療、去除紋身、暗瘡治療、脂肪消減、身體塑形及緊膚等。旗艦產品包括Soprano、Harmony、Accent及FemiLift系列,主要向醫療美容機構直銷或透過分銷商銷售。
Listing Date2017-09-19
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)3079895 以色列凱撒利亞工業園區哈哈拉什街18號Ofek 15號樓
Business Address (Hong Kong)皇后大道東1號 太古廣場三座 28樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitesisram-medical.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 8.88 / shares
Offer Price RangeTo be extracted
Lot Size400 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2017-09-05 to 2017-09-08
Global Offering Shares110,000,000 shares
HK Public Offer Shares (Initial)11,000,000 shares (10.0%)
Public Offer Lots (Initial)27,500lots (Pool A13,750lots,Pool B13,750lots)
International Placing Shares (Initial)99,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO440,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share5.8%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 976,800,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.25B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +651%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約8.5百萬美元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 2014201520162017-03
Revenue 101,321110,406118,15632,647
Cost of sales -49,459-53,043-55,933-15,174
Gross profit 51,86257,36362,22317,473
Other income and gains, net 281450719971
Selling and distribution expenses -16,646-18,590-21,380-5,379
Administrative expenses -10,166-11,121-12,989-2,370
Operating profit 16,65918,23518,8288,049
Net finance costs -7,336-7,308-6,968-1,711
Profit before tax 9,32310,92711,8606,338
Income tax expense -2,618-2,334-3,359-1,288
Profit for the year 6,7058,5938,5015,050
Profit attributable to owners 5,9437,8148,0555,050
Balance Sheet
Item 2014201520162017-03
Cash and cash equivalents 36,79339,30641,65346,546
Trade and bills receivables 22,26522,66328,20730,304
Inventories 18,43121,50121,95524,632
Total current assets 79,59485,64594,968105,892
Total assets 270,383272,992279,161289,099
Total current liabilities 29,33041,43846,97250,461
Total liabilities 245,261240,447238,675243,216
Total equity 25,12232,54540,48645,883
Equity attributable to owners 25,12232,54540,48645,883
Interest-bearing borrowings 67,34159,00348,91849,020
Cash Flow Statement
Item 2014201520162017-03
Net cash from operating activities 22,80715,84716,0134,468
Net cash from investing activities -8,503-2,009-4,182-1,480
Net cash from financing activities -16,413-12,333-13,052425
Net increase in cash -2,1091,505-1,2213,413
Depreciation of PP&E 590644720221
Amortisation of intangible assets 4,8284,8824,8851,192
Purchase of PP&E -579-923-1,039-187
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 8.12
First Day OpenHK$ 8.79
First Day Change-8.56%
First Day Volume38948500.0
First Day Turnover329538000.0
Use of Proceeds
1、約18.6%,或約128.4百萬港元,預期用于擴展我們的銷售渠道及分銷網絡以及加強我們的營銷力度; 2、約18.6%,或約128.4百萬港元,用于資本開支; 3、約14.0%,或約96.3百萬港元,預期用于研究及開發活動; 4、約9.3%,或約64.2百萬港元,預期將用于償還關聯方復星實業(香港)有限公司的收購貸款; 5、約29.5%,或約202.5百萬港元,預期將用于策略性收購、設立戰略合作關系,以及其他業務發展; 6、約10.0%,或約68.9百萬港元,預期用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
中国国际金融香港证券有限公司 CE AEN894 Jefferies Hong Kong Limited CE ATS546
Overall Coordinators (3)
中国国际金融香港证券有限公司 CE AEN894 Jefferies Hong Kong Limited CE ATS546 Fosun International Securities Limited CE AAF432
Joint Bookrunners (5)
中国国际金融香港证券有限公司 CE AEN894 Jefferies Hong Kong Limited CE ATS546 Fosun International Securities Limited CE AAF432 海通国际证券有限公司 CE AAF806 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Lead Managers (5)
中国国际金融香港证券有限公司 CE AEN894 Jefferies Hong Kong Limited CE ATS546 Fosun International Securities Limited CE AAF432 海通国际证券有限公司 CE AAF806 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 纽顿医学美容集团有限公司 29,637,888 HKD — 0.76% — 6 months 2018-03-19
2 上海自贸试验区一期股权投资基金合伙企业(有限合伙) 116,999,328 HKD — 2.99% — 6 months 2018-03-19
3 升泰有限公司 77,998,368 HKD — 2.00% — 6 months 2018-03-19

Directors & Management

PositionChinese nameEnglish Name
Chairman劉毅—
Company Secretary盧綺霞—
No director data available.

Major Shareholders

Major Shareholders & Holdings復星醫藥透過其全資附屬公司(包括CML及能)間接持有本公司已發行股份約51.77%(假設最高發售價12.35港元)或52.96%(假設最低發售價8.88港元)。郭廣昌先生透過FIHL、FHL、復星國際等間接持有本公司已發行股份約52.96%。
About this page

This page shows Sisram Med (01696) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect